Protara Therapeutics Reports $21.7 Million Net Loss in Q2 2026, Driven by Increased Operating Expenses

Protara Therapeutics, Inc. reported a net loss of $21.7 million for the second quarter of 2026, compared to a loss of $15.0 million in the same period last year. For the six months ending June 30, 2026, the company recorded a net loss of $39.5 million, up from $26.9 million in the first half of 2025. The increase in losses is attributed to higher operating expenses, which rose to $23.3 million in Q2 2026 from $16.6 million in Q2 2025, driven primarily by increased research and development costs associated with ongoing clinical trials for its product candidates, TARA-002 and IV Choline Chloride.

Research and development expenses for the second quarter of 2026 totaled $17.0 million, reflecting a significant increase of approximately $6.2 million compared to the prior year. This rise was largely due to higher direct expenses related to clinical trials and increased personnel costs. General and administrative expenses also increased to $6.4 million from $5.8 million year-over-year, primarily due to higher personnel-related costs. The company reported total operating expenses of $43.0 million for the first half of 2026, compared to $30.7 million in the same period of 2025.

Protara's financial position showed a decline in cash and cash equivalents, which decreased to $17.1 million as of June 30, 2026, down from $49.7 million at the end of 2025. The company’s total assets were reported at $176.1 million, a decrease from $209.5 million at the end of the previous fiscal year. The accumulated deficit increased to approximately $341.9 million, reflecting the ongoing investment in clinical development without any current revenue generation.

In terms of strategic developments, Protara is advancing its clinical programs, particularly TARA-002, which is being evaluated in ongoing trials for non-muscle invasive bladder cancer (NMIBC) and lymphatic malformations (LMs). The company has initiated the ADVANCED-2 trial for TARA-002 in NMIBC and expects to complete enrollment for the registrational cohort by the fourth quarter of 2026. Additionally, Protara is pursuing IV Choline Chloride for patients on parenteral support, with a Phase 3 trial (THRIVE-3) currently underway.

Looking ahead, Protara anticipates continued operational losses as it invests in the development of its product candidates. The company has indicated that it will need to raise additional capital to support its ongoing clinical trials and operational needs. Despite the challenges, Protara remains focused on its strategic goals and is optimistic about the potential of its therapies to address unmet medical needs in oncology and rare diseases.